Nanopath Inc., a point-of-care diagnostics company that facilitates high-quality molecular testing in minutes, has received $4 million in federal funding.
Two grants were granted to the company: a $3 million grant from the National Institutes of Health (NIH) and a $1 million grant from the National Science Foundation (NSF).
The Small Business Innovation Research (SBIR) Programme, a competitive initiative that aims to encourage the development of technological innovations by small businesses, awarded both grants. The company’s total funding exceeds $15 million as a result of these grants.
Read also – [Funding News] CA-based Kudos Secures $10.2Million in Series A Round Funding
The point-of-care diagnostic instrument for women’s health will be developed with the assistance of the funding.
Nanopath is committed to enhancing health equity worldwide, beginning with women’s health, through a proprietary molecular diagnostic testing platform, under the leadership of CEO Amogha Tadimety and President and CTO Alison Burklund, Ph.D., co-founder.
The company is actively expanding its pipeline of test offerings through clinical collaborations with prestigious institutions in New England and has developed advanced prototypes of both its disposable test cartridge and benchtop readout instrument.
About Nanopath
Nanopath is a molecular diagnostics company that subverts conventional testing methodologies. Through a single office visit, they endeavour to enhance the health of women by offering clinically actionable and granular information.
